\n\tNovo Nordisk has said it is aware of claims alleging that data copied without authorisation from its systems has been published online. There had been reports that a hacking group had stolen more than 1 terabyte (TB) of company data, after an alleged $25 million extortion demand was refused.\u00a0<\/p>\n
\n\tIn an official statement, the Danish pharmaceutical major said it is treating the matter seriously and has continued monitoring its systems, while maintaining normal operations across its key platforms. The company also confirmed that it is in contact with relevant authorities as part of its response to the reported incident.\u00a0<\/p>\n
\n\t\u201cNovo Nordisk is aware of claims that data allegedly copied externally without authorisation from our systems has been published online. We take this matter seriously and maintain continued operations of our main platforms. We are in contact with the relevant authorities,\u201d the company said in a statement.<\/p>\n
\u00a0
\n\u00a0<\/p>\n
\n\tNovo Nordisk has maintained a presence in India since 1994, with its headquarters in Bengaluru. The company\u2019s insulins have been available in the country since 1935, marking more than 85 years of supply. Its India unit currently employs over 1,600 people and operates as a fast-growing multinational pharmaceutical company. Focused on diabetes care and haemophilia management, the company also expanded its portfolio in India with the introduction of its once-weekly injectable weight-loss drug Wegovy (semaglutide), launched prior to its patent expiry in March this year.\u00a0<\/p>\n
\u00a0<\/p>\n
\n\tThe company further stressed that protecting the security and integrity of its systems remains a top priority, alongside ensuring uninterrupted delivery of products and support services to patients globally.<\/p>\n
\u00a0<\/p>\n
\n\tWhile Novo Nordisk did not confirm the scale or authenticity of the alleged breach, the statement comes amid growing concerns over ransomware-style attacks targeting large multinational corporations, particularly within the healthcare and pharmaceutical sectors, where sensitive research, patient-related information, and proprietary data are often considered high-value targets.<\/p>\n
\u00a0<\/p>\n
\n\tData extortion incidents have become increasingly frequent, with threat actors often claiming large-scale data theft to pressure organisations into paying ransom demands. However, companies frequently caution that such claims are not always independently verified at the time they are made public.<\/p>\n
\u00a0<\/p>\n
\n\tNovo Nordisk has not disclosed further technical details about the alleged incident, and investigations are understood to be going on, with support from relevant authorities and cybersecurity teams.<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":" Novo Nordisk has said it is aware of claims alleging that data copied without authorisation from its…\n","protected":false},"author":2,"featured_media":112174,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[55487,3499,16616,55677,56355,55299,54867,272,40809,55346],"class_list":["post-112173","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-cyberattack","tag-cybersecurity","tag-data-breach","tag-data-theft","tag-extortion-demand","tag-hacking-group","tag-healthcare-cybersecurity","tag-novo-nordisk","tag-pharmaceutical-sector","tag-ransomware"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116777099532340222","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/112173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=112173"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/112173\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/112174"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=112173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=112173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=112173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}